section name header

Pronunciation

aye-KAR-bose

Classifications

Therapeutic Classification: antidiabetics

Pharmacologic Classification: alpha glucosidase inhibitors

Indications

REMS


Action

  • Lowers blood glucose by inhibiting the enzyme alpha-glucosidase in the GI tract. Delays and reduces glucose absorption.
Therapeutic effects:
  • Lowering of blood glucose in diabetic patients, especially postprandial hyperglycemia.

Pharmacokinetics

Absorption: <2% systemically absorbed; action is primarily local (in the GI tract).

Distribution: Unknown.

Metabolism/Excretion: Minimal amounts absorbed are excreted by the kidneys.

Half-Life: 2 hr.

Time/Action Profile

(effect on blood glucose)

ROUTEONSETPEAKDURATION
POunknown1 hrunknown





Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

GI: abdominal pain, diarrhea, flatulence, liver enzymes

Interactions

Drug-drug:

Drug-Natural Products:

Route/Dosage

Availability

(Generic available)

Assessment

Lab Test Considerations:

Toxicity and Overdose:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Precose

Canadian Brand Names

Glucobay